{"organizations": [], "uuid": "540859a368dc75b520a5e891d912cd362e4c0424", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-valeant-announces-licensing-agreem/brief-valeant-announces-licensing-agreement-with-kaken-pharma-for-psoriasis-treatment-idUSFWN1QH1JN", "country": "US", "domain_rank": 408, "title": "BRIEF-Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T03:02:00.000+02:00", "replies_count": 0, "uuid": "540859a368dc75b520a5e891d912cd362e4c0424"}, "author": "", "url": "https://www.reuters.com/article/brief-valeant-announces-licensing-agreem/brief-valeant-announces-licensing-agreement-with-kaken-pharma-for-psoriasis-treatment-idUSFWN1QH1JN", "ord_in_thread": 0, "title": "BRIEF-Valeant Announces Licensing Agreement With Kaken Pharma For Psoriasis Treatment", "locations": [], "entities": {"persons": [], "locations": [{"name": "canada", "sentiment": "none"}], "organizations": [{"name": "kaken pharma for psoriasis treatment february", "sentiment": "negative"}, {"name": "kaken pharmaceutical co.", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "kaken pharma for psoriasis treatment reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - Valeant:\n* ANNOUNCES LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE NEW CHEMICAL ENTITY FOR PSORIASIS\n* ‍UNDER TERMS OF LICENSING AGREEMENT, KAKEN GRANTED TO CO EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE TOPICAL PRODUCTS CONTAINING KP-470​\n* ‍WILL HAVE RIGHTS TO DEVELOP AND COMMERCIALIZE PRODUCTS WITH KP-470 IN UNITED STATES, CANADA, AND WESTERN AND EASTERN EUROPE​\n* ‍KAKEN TO RECEIVE UPFRONT CASH PAYMENT AND HAS POTENTIAL TO RECEIVE CERTAIN DEVELOPMENT-BASED MILESTONE PAYMENTS\n* ‍ADDITIONALLY, KAKEN WILL RECEIVE ROYALTIES ON VALEANT‘S NET SALES OF PRODUCTS​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-02-28T03:02:00.000+02:00", "crawled": "2018-02-28T03:24:13.006+02:00", "highlightTitle": ""}